Top Tweets for #KeyNote177
📍#KEYNOTE177 confirma el impacto de #pembrolizumab en #mCRC MSI-H/dMMR con>5 años de seguimiento:
https://t.co/XX2t8L0SOy
🔹Mediana de SG: 77,5 vs 36,7 meses (HR 0,73)
🔹SG a 5 años: 54,8% vs 44,2%
🔹Mediana de SLP: 16,5 vs 8,2 meses (HR 0,60)
#Pembrolizumab continued to show durable antitumour activity compared with chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic #ColorectalCancer, #KEYNOTE177 study finds
10.1016/S1470-2045(22)00197-8
Our new paper is out - great collaboration with @lab_pearson from @UChiPritzker 🇪🇺🇺🇸 #AI based #MSI testing in #colorectal #cancer could save 💵💶 @UniklinikAachen @NCT_HD @rwth #keynote177
Q: How could #digitalpathology #AI affect cancer healthcare systems cost and care delivery if we deployed existing models *today*? 🤖vs🦀
Check out our new cost-model use case manuscript in @FrontiersIn @FrontOncology:
https://t.co/yC19L0xzkS
#GI21 #ASCOGI21 @ASCO
#KEYNOTE177: Phase III randomized study of #pembrolizumab vs #chemotherapy for #microsatelliteInstabilityHigh advanced #ColorectalCancer
@ASCO_pubs @pashtoonkasi @NiuSanford
@realbowtiedoc @ShaalanBeg @PamelaKunzMD
🗞 L'article, publicat recentment a @NatRevClinOncol, aprofundeix sobre l'assaig #KEYNOTE177 i compta amb el punt de vista de @TaberneroJosep, director del VHIO, sobre la importància de l'estudi per als pacients amb càncer colorectal.👇 https://t.co/Qx5bACK4ce
🗞 El artículo, publicado recientemente en @NatRevClinOncol, profundiza sobre el ensayo #KEYNOTE177 y cuenta con el punto de vista de @TaberneroJosep, director del VHIO, sobre la importancia de este estudio para los pacientes con cáncer colorrectal.👇https://t.co/7KoVRssw2w
Happy to share our map of #CRC response to immunotherapy incl. #KEYNOTE177 samples. Huge effort by @RedaKeddar @AmeAchaSag Michele, Lucia (not on Twitter) @JoSpencerLab clinical colleagues @uclcancer fabulous STPs @TheCrick and many more. Summary 👇 1/8 https://t.co/vklPXFti7F
#Pembrolizumab in Microsatellite-Instability–High #Advanced #ColorectalCancer #KEYNOTE177
@pashtoonkasi @LorenzaRimassa @fireflyann @ShuchiGulati
https://t.co/INJg99lHuk
How do we interpret future 1st line ICB studies when a significant % of pts receive IO in later lines of treatment? Striking lack of OS benefit in #attraction4 , while PFS sign better. May be the case for #keynote177 in dMMR #crc as well #ESMO20
#KeyNote177 looking at Quality of Life for #MSI #colorectalcancer - physical as well as social functioning.
#ESMO20 #CRCSM
Andre et al, KEYNOTE-177 QoL results
Pembro vs standard chemotherapy in MSI-H/dMMR mCCR:
- better health-related QoL
- prolonged TTD for global health status/QoL (HR 0.61), physical functioning (HR 0.50), social functioning (HR 0.53) and fatigue (HR 0.48)
#ESMO20
As per Thierry Andre on todays #ESMO20 meeting we will likely not know which pts on #Keynote177 were germline Lynch vs. somatic MSI-H mutated #colorectal #cancer patients. #crcsm @VUMC_Cancer @VUMChealth #clinicaltrials #cancerresearch @Merck @OncoAlert
#ESMO20
#6 on @PTarantinoMD Top 10 list
#KeyNote177 - Quality of Life for #MSI #ColorectalCancer patients receiving Pembro in the 1st line.
#CRCSM #OncoAlert
Hard, yet exciting exercise, trying to pick a TOP10 of upcoming #ESMO20 Abstracts
A multitude of practice-changing trials in breast, lung, gastric cancer, CRC and so much more!
Don’t miss this important appointment - registration still open, free for @myESMO members!
@OncoAlert
#WorldGI2020 👇🏾THIS is what we need to figure out.
Who are these MSI⬆️patients who don’t respond to upfront #immunotherapy. 💡
🔴True progression
🟡?not true dMMR (confirm MSI/NGS)
🟢TMB
🟠?KRAS➕
🟣host immune system📉
Other thoughts/ideas❓
@myESMO @OncoAlert
#CRCSM
OncKIP faculty member @BraghiroliIgnez shares a personal highlight from #ASCO20: results from #KEYNOTE177 study of pembrolizumab vs. chemotherapy in MSI-H/dMMR metastatic colorectal cancer #crcsm
Great news for US patients with MSI metastatic #colorectalcancer . Hopefully Europe will follow soon. Hope to see the publication of #keynote177 soon!
Just Out📣 @US_FDA 🇺🇸Approves1️⃣st Line pembrolizumab in MSI-H/dMMR 🧬Metastatic #ColorectalCancer
This marks the 1️⃣st #immunotherapy approved for this patient population as 1️⃣st line treatment & administered without also giving #chemotherapy 🧪
https://t.co/CWOGieBNdh
#Pembrolizumab should be considered a new standard of care as first-line therapy for MSI-H metastatic #colorectalcancer, says Thierry Andre. Slides are from a press preview. Full data to be presented as LBA4 during the plenary. https://t.co/go6fgnH4KO #ASCO20 #ASCO2020 #crcsm
Just in time for the FDA approval!
(of Pembrolizumab in the 1st line for #MSI #colorectalcancer)
Dr. Weinberg discusses #KeyNote177 during first 7 minutes - some interesting comments re possible future directions
@benweinbergmd
JUST RELEASED: In our latest episode of #OncLiveOnAir, @benweinbergmd, of @LombardiCancer, discusses the clinical implications of recent data presented at the 2020 ASCO Virtual Scientific Program on the treatment of CRC. #ASCO20 #crcsm Listen now: https://t.co/JzDPZCiHaW
June IS Immunotherapy Month...
what with TWO FDA approvals for I/O in #colorectalcancer
But good to remember all the points brought up in #KeyNote177 so that the research keeps moving forward and the best therapy is found for #MSI patients (and hope that helps MSS pts).
#CIM20
#ASCO20 Excellent discussion from prof. Overman on practice-changing results of #Keynote 177, raised questions & next steps #Oncoalert
Excited to be part of this outstanding and important conference. Thanks @IEOufficiale for the opportunity to share highlights on #colorectalcancer!! #ASCO20 #CRC
#keynote177 #IDEA #RAPIDOtrial
@CCAlliance starting it off with #KeyNote177 for #MSI #mCRC patients in the 1st line.... Drs. Lieu & @marshalj23
#CRCLive #CRCSM #ASCO20
Last Seen Hashtags on Sotwe
türksikiş
Seen from Turkey
hijabi
Seen from United Kingdom
Almost_done
Seen from Turkey
mgai()****************************** filter:videos
Seen from Netherlands
incesto hija
Seen from Mexico
fisha
Seen from France
vgkbocil
Seen from Indonesia
full
Seen from United States
Maharashtra Growth
Seen from Norway
melikebulucankurt
Seen from Turkey
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
118.8M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.3M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.7M followers